Beyang Closes Oversubscribed $30 Million Series A Financing

Second-generation Menin inhibitorNovel ophthalmic therapyPositive

AI Analysis

Summary

Beyang closed an oversubscribed $30 million Series A financing round to advance its AI-driven ExCEED platform and clinical development of differentiated pipeline candidates including a second-generation Menin inhibitor and novel ophthalmic therapy.

Importance:5/10

Sentiment:

0.60

Series A financingOversubscribedAI platformMenin inhibitorOphthalmic therapyPipeline advancement

Related Companies

$GBIO $INTI $GBCYD $CHHE

Read the original article

Published by PR Newswire Biotech on August 12, 2026 9:25 AM

Read Original